Isoprenaline Monograph: β1/β2 Agonism, Bradyarrhythmia Context and Infusion Hazards

Evidence-informed pharmacology monograph, reviewed 10 November 2026. Educational content; drug administration and prescribing require current local labels, institutional protocols and individualized clinical assessment.

Overview and correction of prior claims

Isoprenaline (isoproterenol) is a synthetic nonselective β1/β2 adrenergic agonist with negligible direct α receptor activity. Historical uses included bronchodilation and cardiovascular support, but modern indications for injectable products are more restricted. The original article incorrectly implied routine treatment of acute myocardial infarction and ordinary severe asthma; those uses are inappropriate as generalized recommendations. Its chemical structure is a catechol-substituted phenylethanolamine, not the dimethoxybenzyl propanol named in the old monograph [1,2].

Mechanism and hemodynamics

β1 stimulation activates Gs/cAMP and increases cardiac calcium cycling, producing positive chronotropy, inotropy and enhanced AV conduction. β2 stimulation causes airway and skeletal-muscle arterial relaxation, decreasing vascular resistance and often diastolic arterial pressure. Heart rate and cardiac output can increase, but total pressure response is variable and myocardial oxygen demand rises. Unlike norepinephrine, isoprenaline has no strong α1 vasoconstrictor component [1].

Contemporary labeled indications

A 2026 US label authorizes isoproterenol injection for improving hemodynamic status in distributive shock or shock due to reduced cardiac output, and for bronchospasm during anesthesia. Clinical use in selected bradyarrhythmias or electrophysiology-laboratory protocols may occur under specialist supervision. Routine treatment of myocardial infarction, outpatient asthma or undifferentiated shock is not justified by the label and may worsen ischemia or tachyarrhythmias [2].

Administration and pharmacokinetics

Intravenous preparations act rapidly and are titrated in monitored care according to indication. Catecholamine metabolism, including catechol-O-methyltransferase pathways, contributes to its short duration. Continuous ECG, HR, BP, oxygenation and markers of perfusion are necessary during infusion. Fluid status, pressor needs and the cause of shock must be assessed; an increase in heart rate is not by itself proof of improved organ perfusion [1,2].

Contraindications and adverse reactions

The 2026 US label lists tachycardia, ventricular arrhythmias and angina pectoris as contraindications. Rapid ventricular rhythm, ectopy, myocardial ischemia, palpitations, tremor, hypotension and metabolic effects can occur. Sulfite sensitivity may produce allergic-type reactions with certain formulations. Particularly in coronary disease, forcing tachycardia can cause harm [2].

Drug interactions

Do not administer isoproterenol and epinephrine simultaneously under labeled guidance because combined catecholamine effects can precipitate serious arrhythmias. Monoamine oxidase inhibitors, tricyclic antidepressants and thyroid medication may potentiate sympathetic responses. β blockers attenuate cardiostimulant and bronchodilator responses. Review concurrent catecholamine infusions and electrolyte status before starting therapy [2].

Teaching synthesis

A useful comparison is that isoprenaline activates β1 and β2 without appreciable α1, dobutamine predominantly improves β1-mediated contractility with mixed vascular activity, and norepinephrine produces strong α1 vasoconstriction with β1 support. Choosing among them requires clinical hemodynamic assessment, not only receptor memorization [1].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Isoproterenol hydrochloride injection: prescribing information, revised March 2026. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=051acbc2-7bf8-4059-e063-6394a90a115b
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *